RxDoctor Payments Data

Mark Dodson, MD

Family Medicine · Corpus Christi, TXNPI 1730297821

Payments from drug & device makers

$1,256in general payments, 2019–2025

Across 45 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$190
  • Novo Nordisk$176
  • Lilly USA, LLC$160
  • United Therapeutics Corporation$136
  • Idorsia Pharmaceuticals US Inc$106
  • Actelion Pharmaceuticals US, Inc.$101
  • plus $386 from 14 others

What the payments were for

  • Food & beverage$1,15992%
  • Education$978%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,256 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,172
Medicare patients
125
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$52,897
OzempicSemaglutide38$42,766
EliquisApixaban26$32,195
TrulicityDulaglutide11$14,234
SynthroidLevothyroxine Sodium18$1,949
Nebivolol Hcl23$1,224
Levothyroxine Sodium88$986
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$907
Colesevelam Hcl13$898
Atorvastatin Calcium72$888
Omeprazole48$754
Bupropion XlBupropion Hcl25$745
Valsartan23$667
Potassium Chloride41$650
Sucralfate11$650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$160$67,13155 claims
Novo NordiskOzempic$176$42,76638 claims
AbbVieSynthroid$21$1,94918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →